The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
Hosted on MSN
Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide
We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Pfizer Inc. stands fifth among them. Pfizer Inc. (NYSE:PFE), a global pharmaceutical leader, continues to ...
The Comirnaty 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, a descendant of JN.1. The Food and Drug Administration (FDA) has approved Comirnaty ® (LP.8.1-adapted monovalent ...
Even without accounting for the COVID declines that have punctuated Pfizer’s earnings in recent years, the company’s vaccines business appeared to be on the back foot in the third quarter, brought low ...
NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback